Adherium Expands Its International Presence, Announces Senior Appointment

23 February 2017: Adherium Limited (ASX : ADR), link here

a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced the appointment of a new Vice President of Business Development for its key markets outside of North America and Europe.

Erin Wansbrough will lead Adherium’s partnering and market expansion for the ‘Rest of World’ territories, including Asia Pacific and the Middle East where Adherium already has approvals to market its SmartinhalerTM products in China, Australia and New Zealand. Erin will be operating out of the Company’s existing Asia Pacific base in Auckland, New Zealand. Ms Wansbrough joins Adherium after a successful career over the last 16 years that spans multiple industries including pharmaceuticals, healthcare, biotechnology, and ICT across both private and public sectors. As a senior professional, Erin has a strong track record with innovative, high-growth companies. Erin began her career with Life Technologies in New Zealand in Product and Sales Management. She then went on to work for AstraZeneca and GSK in a Sales Management capacity before joining Genesis Research & Development Corporation as Business Development Manager. Erin is currently a Director of the New Zealand Technology Industry Association (NZTech) and joins Adherium from Callaghan Innovation where she was responsible for building the Business Innovation Group. Prior to this, Erin spent a period of time in Australia as Business Development Manager with IMBcom, a private company dedicated to the commercialisation of research from one of the leading biotechnology research organisations in Australia, The University of Queensland. Garth Sutherland, Group CEO of Adherium said: “I am delighted to welcome Erin to Adherium’s growing global Business Development team. This is a key milestone for us as we continue to build our commercial capabilities to attract and service new customers. Erin has a proven track record of executing commercial partnerships and business development management." Erin Wansbrough added: “It’s been exciting to watch the progress of the company over the last few years and it will be a privilege to join the team to help build Adherium’s future. Fulfilling the promise of empowering people with chronic conditions to live the life they want.” ABOUT ADHERIUM Adherium (ASX:ADR) is an Australian Securities Exchange listed company which develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease. Adherium operates globally from bases in the USA, Europe and Australasia. Adherium is a provider of digital health solutions to patients, pharmaceutical companies, healthcare providers and contract research organizations. The Company’s proprietary Smartinhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. Adherium has the broadest range of "smart" medication sensors for respiratory medications globally. The Smartinhaler™ platform has so far been used in more than 65 projects (clinical, device validation or other) and has been referenced in 56 peer reviewed journal articles. Clinical outcomes data has proven that the Smartinhaler™ platform can improve adherence by up to 59% in adults and 180% in children and reduce severe episodes by 60% in adults, leading to improved quality-of-life and demonstrating a substantial gain over current best practice treatment. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets. www.adherium.com www.smartinhaler.com Enquiries: At Adherium: Media enquiries: Investor Relations Julia Chambers Head of Corporate Development M: +64 27 807 8153 E: investors@adherium.com Australia and New Zealand Rudi Michelson Monsoon Communications D: +61 3 9620 3333 E: rudim@monsoon.com.au Rest of World Erin Wansbrough Vice President Business Development Rest of World M: +64 21 766 083 E: erinw@adherium.com North America James Hattersley Senior Vice President Business Development North America M: +1 610 955 5886 E: jamesh@adherium.com North America Erich Sandoval Lazar Partners D: +1 213-908-6226 E: esandoval@lazarpartners.com Europe Scott Fleming Senior Vice President Business Development Europe M: +31 646 876 989 E: scottf@adherium.com Europe Sue Charles/Rozi Morris Instinctif Partners D: +44 20 7457 2020 E: adherium@instinctif.com